73981-34-7
Chemical Structure
Kamebakaurin
- CAS No.: 73981-34-7
- Formula:C20H30O5
- Molecular Weight:350.45
IUPAC Name: (1S,4aR,6R,6aR,9S,11aS,11bR,12R)-1,6,12-trihydroxy-11b-(hydroxymethyl)-4-methyl-8-methylenedodecahydro-6a,9-methanocyclohepta[a]naphthalen-7(1H)-one
InChIKey: USHUXAOWOCIZFR-MOFKLBIISA-N
SMILES: O[C@H]1[C@@]23[C@](CC[C@@]1([H])C(C3=O)=C)([H])[C@]4([C@](C(C)(CC[C@@H]4O)C)([H])C[C@H]2O)CO
Biological Activity: Kamebakaurin is an orally active diterpenoid compound that can be isolated from Isodon excia (Maxin.). Kamebakaurin can inhibit NF-κB activation by directly targeting the DNA-binding activity of p50. Kamebakaurin can induce apoptosis and cell cycle arrest in tumor cells. Kamebakaurin has anti-inflammatory and anti-tumor activities[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Kamebakaurin | 99.64% | Kamebakaurin is an orally active diterpenoid compound that can be isolated from Isodon excia (Maxin.). Kamebakaurin can inhibit NF-κB activation by directly targeting the DNA-binding activity of p50. Kamebakaurin can induce apoptosis and cell cycle arrest in tumor cells. Kamebakaurin has anti-inflammatory and anti-tumor activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee JH, et al. Kaurane diterpene, kamebakaurin, inhibits NF-kappa B by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-kappa B target genes. J Biol Chem. 2002 May 24;277(21):18411-20. [Content Brief]
- [2]. Wang KS, et al. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. Oncol Rep. 2016 Apr;35(4):2045-52. [Content Brief]
- [3]. Yoshioka H, et al. Suppressive effect of kamebakaurin on acetaminophen-induced hepatotoxicity by inhibiting lipid peroxidation and inflammatory response in mice. Pharmacol Rep. 2017 Oct;69(5):903-907. [Content Brief]
